Clinical impact of serum proteins on drug delivery

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 429-445

  Kratz, Felix ^a   Elsadek, Bakheet ^b  

^a TUMOR BIOLOGY CENTER   (Germany)

^b Al Azhar University   (Egypt)

Author keywords

Drug carrier; Drug delivery; Human serum albumin; Prodrugs; Serum proteins; Transferrin

Indexed keywords

DRUG CARRIER; HUMAN SERUM ALBUMINS; PRODRUGS; SERUM PROTEINS; TRANSFERRIN;

BODY FLUIDS; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; EXPERIMENTS; FATTY ACIDS; GLUCOSE; MONOCLONAL ANTIBODIES; NANOPARTICLES; TUMORS;

PEPTIDES;

ALBINTERFERON ALPHA2B; ALBUMIN; AT 103; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALLIUM 67; GALLIUM 68; GEMCITABINE; GLUCOSE; HUMAN SERUM ALBUMIN; INNO 206; INSULIN DETEMIR; LIRAGLUTIDE; METHOTREXATE; NANOCOLL TC 99M; OZORALIZUMAB; PACLITAXEL; PLASMA PROTEIN; TECHNETIUM 99M; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCINTISCANNING; COMPLEX FORMATION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEAD AND NECK CANCER; HEPATITIS; HEPATITIS C; HUMAN; INSULIN TREATMENT; KIDNEY CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STOMATITIS;

ALBUMINS; ANIMALS; ARTHRITIS, RHEUMATOID; DIABETES MELLITUS; DRUG CARRIERS; HEPATITIS C; HUMANS; ISOTOPE LABELING; NEOPLASMS; TRANSFERRIN;

EID: 84862702122     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.11.028     Document Type: Review

References (94)

1. L.Z. Benet, B.A. Hoener, Changes in plasma protein binding have little clinical relevance, Clin. Pharmacol. Ther. 71 (3) (2002) 115-121.
2. N.A. Kratochwil, W. Huber, F. Muller, M. Kansy, P.R. Gerber, Predicting plasma protein binding of drugs: a new approach, Biochem. Pharmacol. 64 (9) (2002) 1355-1374.
3. D.R. Hall, J.M. Hadden, G.A. Leonard, S. Bailey, M. Neu, M. Winn, P.F. Lindley, The crystal and molecular structures of diferric porcine and rabbit serum transferrins at resolutions of 2.15 and 2.60 A, respectively, Acta Crystallogr. D Biol. Crystallogr. 58 (Pt 1) (2002) 70-80.
4. S. Sugio, A. Kashima, S. Mochizuki, M. Noda, K. Kobayashi, Crystal structure of human serum albumin at 2.5 A resolution, Protein Eng. 12 (6) (1999) 439-446.
5. F. Kratz, U. Beyer, Serum proteins as drug carriers of anticancer agents: a review, Drug Deliv. 5 (1998) 281-299.
6. U. Testa, E. Pelosi, C. Peschle, The transferrin receptor, Crit. Rev. Oncog. 4 (3) (1993) 241-276.
7. T. Peters, Serum albumin, Adv. Protein Chem. 37 (1985) 161-245.
8. M. Fasano, S. Curry, E. Terreno, M. Galliano, G. Fanali, P. Narciso, S. Notari, P. Ascenzi, The extraordinary ligand binding properties of human serum albumin, IUBMB Life 57 (12) (2005) 787-796.
9. C. Bertucci, E. Domenici, Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance, Curr. Med. Chem. 9 (15) (2002) 1463-1481.
10. A. Cantafora, I. Blotta, Neutral lipids production, transport, utilization, Anticancer Res. 16 (3B) (1996) 1441-1449.
11. B. Yu, X. Zhao, L.J. Lee, R.J. Lee, Targeted delivery systems for oligonucleotide therapeutics, AAPS J. 11 (1) (2009) 195-203.
12. Z.M. Qian, H. Li, H. Sun, K. Ho, Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway, Pharmacol. Rev. 54 (4) (2002) 561-587.
13. H. Li, Z.M. Qian, Transferrin/transferrin receptor-mediated drug delivery, Med. Res. Rev. 22 (3) (2002) 225-250.
14. B. Elsadek, F. Kratz, Impact of albumin on drug delivery - New applications on the horizon, J. Control. Release 157 (1) (2012) 4-28.
15. F. Kratz, Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles, J. Control. Release 132 (3) (2008) 171-183.
16. L. Fiume, L. Bolondi, C. Busi, P. Chieco, F. Kratz, M. Lanza, A. Mattioli, G. Di Stefano, Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine, J. Hepatol. 43 (4) (2005) 645-652.
17. R. Bansal, J. Prakash, M. Ruijter, L. Beljaars, K. Poelstra, Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis, Mol. Pharm. 8 (5) (2011) 1899-1909.
18. J. Prakash, E. de Jong, E. Post, A.S. Gouw, L. Beljaars, K. Poelstra, A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier, J. Control. Release 145 (2) (2010) 91-101.
19. K. Temming, D.L. Meyer, R. Zabinski, P.D. Senter, K. Poelstra, G. Molema, R.J. Kok, Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative, Mol. Pharm. 4 (5) (2007) 686-694.
20. H.A. Macapinlac, A.M. Scott, S.M. Larson, C.R. Divgi, S.D. Yeh, S.J. Goldsmith, Gallium-67-citrate imaging in nuclear oncology, Nucl. Med. Biol. 21 (5) (1994) 731-738.
21. C.L. Edwards, R.L. Hayes, Tumor scanning with 67Ga citrate, J. Nucl. Med. 10 (2) (1969) 103-105.
22. S.G. Ward, R.C. Taylor, Anti-tumor activity of the main-group metallic elements: aluminium, gallium, thallium, germanium, lead, antimony and bismuth, Chapter 1, in: M.F. Gielen (Ed.), Metal-based Antitumor Drugs, Freund Publishing House Ltd., 1988.
23. J.H. Brock, Transferrins; In Metalloproteins, Part 2: Metal Proteins with Nonredox Roles, Verlag Chemie Weinheim Part 2 (1985) 183-263.
24. J.A. Dorth, J.P. Chino, L.R. Prosnitz, L.F. Diehl, A.W. Beaven, R.E. Coleman, C.R. Kelsey, The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans, Ann. Oncol. 22 (2) (2011) 405-410.
25. IAEA, Technetium-99m radiopharmaceuticals : manufacture of kits, International Atomic Energy Agency Vienna 1 (2008) 1.
26. Y.F. Wang, M.H. Chuang, J.S. Chiu, T.M. Cham, M.I. Chung, On-site preparation of technetium-99m labeled human serum albumin for clinical application, Tohoku J. Exp. Med. 211 (4) (2007) 379-385.
27. Y. Nishiyama, Y. Yamamoto, Y. Mori, K. Satoh, H. Takashima, M. Ohkawa, M. Tanabe, Usefulness of Technetium-99m human serum albumin lymphoscintigraphy in chyluria, Clin. Nucl. Med. 23 (7) (1998) 429-431.
28. T. Rink, T. Heuser, H. Fitz, H.J. Schroth, E. Weller, H.H. Zippel, Lymphoscintigraphic sentinel node imaging and gamma probe detection in breast cancer with Tc-99m nanocolloidal albumin: results of an optimized protocol, Clin. Nucl. Med. 26 (4) (2001) 293-298.
29. S. Kim, H.K. Kim, D.Y. Kang, J.M. Jeong, Y.H. Choi, Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, 99mTc-MSA) in stage I non-small cell lung cancer, Eur. J. Cardiothorac. Surg. 37 (6) (2010) 1450-1456.
30. H.K. Kim, S. Kim, J.J. Park, J.M. Jeong, Y.J. Mok, Y.H. Choi, Sentinel node identification using technetium-99m Neomannosyl human serum albumin in esophageal cancer, Ann. Thorac. Surg. (2011).
31. A. Dhabuwala, P. Lamerton, R.S. Stubbs, Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT), BMC Nuclear Med. 5 (2005) 7.
32. K. Suga, N. Kume, N. Matsunaga, K. Motoyama, A. Hara, N. Ogasawara, Assessment of leg oedema by dynamic lymphoscintigraphy with intradermal injection of technetium-99m human serum albumin and load produced by standing, Eur. J. Nucl. Med. 28 (3) (2001) 294-303.
33. Y.J. Hsu, S.H. Lin, Y.F. Lin, F.C. Yu, L.E. Jaiteh, Pitfalls of technetium-99m-labeled human serum albumin scintigraphy for protein-losing enteropathy, Kidney Int. 76 (8) (2009) 911 author reply 911-912.
34. B.K. Adams, H.M. Al Attia, R.A. Khadim, Z.Y. Al Haider, 99Tc(m) nanocolloid scintigraphy: a reliable way to detect active joint disease in patients with peripheral joint pain, Nucl. Med. Commun. 22 (3) (2001) 315-318.
35. R.A. Valdes-Olmos, L. Jansen, C.A. Hoefnagel, O.E. Nieweg, S.H. Muller, E.J. Rutgers, B.B. Kroon, Evaluation ofmammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification, J. Nucl. Med. 41 (9) (2000) 1500-1506.
36. D.H. Henry, N.V. Dahl, PharmD on behalf of the Ferrlecit cancer study group and Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, and Watson Laboratories, Inc., Morristown, N. Community in Oncology 4 (2006) 95-101.
37. G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, J.C. Stewart, G. Hartung, W. Maier-Borst, D.L. Heene, Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia, Crit. Rev. Oncol. Hematol. 26 (2) (1997) 77-100.
38. J. Baselga, M.G. Kris, H.I. Scher, M. Phillips, R.T. Heelan, Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer, Invest. New Drugs 11 (1) (1993) 85-86.
39. B.J. Foster, K. Clagett-Carr, D. Hoth, B. Leyland-Jones, Gallium nitrate: the second metal with clinical activity, Cancer Treat. Rep. 70 (11) (1986) 1311-1319.
40. P. Collery, C. Pechery, Clinical Experience with Tumor-Inhibiting Gallium Complexes, Verlag Chemie VCH, Weinheim, 1993.
41. B.K. Keppler, K.-G. Lipponer, B. Stenzel, F. Kratz, in: B.K. Keppler (Ed.), Metal Complexes as Antitumour Agents, Verlag Chemie,Weinheim, 1993, pp. 392-429.
42. F. Kratz, M. Hartmann, B. Keppler, L. Messori, The binding properties of two anti-tumor ruthenium(III) complexes to apotransferrin, J. Biol. Chem. 269 (4) (1994) 2581-2588.
43. F. Kratz, N. Mulinacci, L. Messori, I. Bertini, B.K. Keppler, Kinetic, spectroscopic and LPLC studies of the interactions of antitumour ruthenium(III) complexes with serum proteins, Metal Ions in Biology and Medicine 2 (1992) 69-74.
44. F. Kratz, B.K. Keppler, M. Hartmann, L. Messori, M.R. Berger, Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in a human colon cancer cell line, Metal-Based Drugs 3 (1) (1996) 15-23.
45. L. Trynda-Lemiesz, A. Karaczyn, B.K. Keppler, H. Kozlowski, Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate( III), J. Inorg. Biochem. 78 (4) (2000) 341-346.
46. F. Lentz, A. Drescher, A. Lindauer, M. Henke, R.A. Hilger, C.G. Hartinger, M.E. Scheulen, C. Dittrich, B.K. Keppler, U. Jaehde, Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study, Anticancer Drugs 20 (2) (2009) 97-103.
47. M. Weaver, D.W. Laske, Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas, J. Neurooncol 65 (1) (2003) 3-13.
48. D.W. Laske, R.J. Youle, E.H. Oldfield, Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors, Nat. Med. 3 (12) (1997) 1362-1368.
49. P. Vishnu, V. Roy, Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer, Breast Cancer 5 (2011) 53-65 (Auckl).
50. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O'Shaughnessy, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer, J. Clin. Oncol. 23 (31) (2005) 7794-7803.
51. W.J. Gradishar, D. Krasnojon, S. Cheporov, A.N. Makhson, G.M. Manikhas, A. Clawson, P. Bhar, Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer, J. Clin. Oncol. 27 (22) (2009) 3611-3619.
52. M. Socinski, I. Vinnichenko, I. Okamoto, J. Hon, V. Hirsh, Results of a randomized, Phase 3 Trial of nab-Paclitaxel (nab-P) and Carboplatin (C) compared with Cremophor-based Paclitaxel (P) and Carboplatin as first-line therapy in advanced Non-small Cell Lung Cancer (NSCLC), Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO), , 2010, Chicago, IL.
53. D.D. Von Hoff, R. Ramanathan, M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, J. Iglesias, M. Hidalgo, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study, American Society of Clinical Oncology (ASCO) annual meeting, 2009.
54. N. Desai, V. Trieu, B. Damascelli, P. Soon-Shiong, SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients, Transl Oncol 2 (2) (2009) 59-64.
55. N. Desai, T. De, S. Ci, L. Louie, V. Trieu, Characterization and in vitro/in vivo dissolution of nab-paclitaxel nanoparticles, American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, 2008.
56. J.E. Schnitzer, gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis, Am. J. Physiol. 262 (1 Pt 2) (1992) H246-H254.
57. C. Tiruppathi, W. Song, M. Bergenfeldt, P. Sass, A.B. Malik, Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway, J. Biol. Chem. 272 (41) (1997) 25968-25975.
58. Z. Wang, C. Tiruppathi, R.D. Minshall, A.B. Malik, Size and dynamics of caveolae studied using nanoparticles in living endothelial cells, ACS Nano 3 (12) (2009) 4110-4116.
59. M.J. Hawkins, P. Soon-Shiong, N. Desai, Protein nanoparticles as drug carriers in clinical medicine, Adv. Drug Deliv. Rev. 60 (8) (2008) 876-885.
60. H. Sage, C. Johnson, P. Bornstein, Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture, J. Biol. Chem. 259 (6) (1984) 3993-4007.
61. O.L. Podhajcer, L.G. Benedetti, M.R. Girotti, F. Prada, E. Salvatierra, A.S. Llera, The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host, Cancer Metastasis Rev. 27 (4) (2008) 691-705.
62. V. Trieu, T. Frankel, E. Labao, P. Soon-Shiong, N. Desai, SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albuminbound paclitaxel (ABI-007) vs taxol, American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA, 2005.
63. V. Trieu, J. Hwang, N. Desai, Nanoparticle Albumin-bound (nab) technology may enhance antitumor activity via targeting of SPARC protein, New Targets and Delivery System for Cancer Diagnosis and Treatment (SKCC), San Diego, CA, 2007.
64. G. Stehle, A. Wunder, H. Sinn, H.H. Schrenk, S. Schutt, E. Frei, G. Hartung, W. Maier-Borst, D.L. Heene, Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats, Anticancer Drugs 8 (9) (1997) 835-844.
65. G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, S. Schutt, W. Maier-Borst, D.L. Heene, The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats, Anticancer Drugs 8 (7) (1997) 677-685.
66. G. Hartung, G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, H.S.L. Kränzle, H.H. Fiebig, W. Maier-Borst, D.L. Heene, W. Queißer, Phase I trial of a methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients, Clin. Cancer Res. 5 (4) (1999) 753-759.
67. A.N. Vis, A. van der Gaast, B.W. van Rhijn, T.K. Catsburg, C. Schmidt, G.H. Mickisch, A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy, Cancer Chemother. Pharmacol. 49 (4) (2002) 342-345.
68. C. Bolling, T. Graefe, C. Lubbing, F. Jankevicius, S. Uktveris, A. Cesas, W.H. Meyer-Moldenhauer, H. Starkmann, M. Weigel, K. Burk, A.R. Hanauske, Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma, Invest. New Drugs 24 (6) (2006) 521-527.
69. B. Elsadek, R. Graeser, A. Warnecke, C. Unger, T. Saleem, N. El-Melegy, H. Madkor, F. Kratz, Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA), ACS Medicinal Chemistry Letters 1 (5) (2010) 234-238.
70. A.M. Mansour, J. Drevs, N. Esser, F.M. Hamada, O.A. Badary, C. Unger, I. Fichtner, F. Kratz, A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2, Cancer Res. 63 (2003) 4062-4066.
71. F. Kratz, R. Mueller-Driver, I. Hofmann, J. Drevs, C. Unger, A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy, J. Med. Chem. 43 (7) (2000) 1253-1256.
72. R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, C. Unger, F. Kratz, INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model, Invest New Drugs 28 (1) (2010) 14-19.
73. F. Kratz, A. Warnecke, K. Scheuermann, C. Stockmar, J. Schwab, P. Lazar, P. Drückes, N. Esser, J. Drevs, D. Rognan, C. Bissantz, C. Hinderling, G. Folkers, I. Fichtner, C. Unger, Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acidsensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound, J. Med. Chem. 45 (2002) 5523-5533.
74. C. Unger, B. Haring, M. Medinger, J. Drevs, S. Steinbild, F. Kratz, K. Mross, Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin, Clin. Cancer Res. 13 (16) (2007) 4858-4866.
75. F. Kratz, I.A. Muller, C. Ryppa, A. Warnecke, Prodrug strategies in anticancer chemotherapy, ChemMedChem 3 (1) (2008) 20-53.
76. A. Huhalov, S. Adams, J. Gu, B. Harms, V. Paragas, L. Luus, S. Nguyen, M. Razlog, R. Overland, S. Oyama, M. Wallace, N. Kohli, K. Olivier, M. Feldhaus, B. Schoeberl, U. Nielsen, C. McDonagh, MM-111: a novel ErbB3 antagonist with potent antitumor activity in ErbB2 over-expressing malignancies, the Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009.
77. C.S. Denlinger, M. Beeram, A.W. Tolcher, L.J. Goldstein, W.J. Slichenmyer, J. Murray, C. McDonagh, K. Andreas, V.M. Moyo, A phase 1-2 and pharmacologic study of MM-111 in patients with advanced, refractory HER2-Positive (HER-2+) cancers, The Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 4-8, 2010.
78. K. Raslova, An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog, Vasc. Health Risk Manag. 6 (2010) 399-410.
79. J. Morales, Defining the role of insulin detemir in Basal insulin therapy, Drugs 67 (17) (2007) 2557-2584.
80. S.K. Garg, The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review, Diabetes Technol. Ther. 12 (1) (2010) 11-24.
81. L.L. Baggio, Q. Huang, X. Cao, D.J. Drucker, An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis, Gastroenterology 134 (4) (2008) 1137-1147.
82. S. Madsbad, U. Kielgast, M. Asmar, C.F. Deacon, S.S. Torekov, J.J. Holst, An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future, Diabetes Obes. Metab. 13 (5) (2011) 394-407.
83. D.J. Drucker, Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis, Mol. Endocrinol. 17 (2) (2003) 161-171.
84. I. Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, Y.S. Youn, Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy, Bioconjug. Chem. 21 (8) (2010) 1513-1519.
85. J.G. Kim, L.L. Baggio, D.P. Bridon, J.P. Castaigne, M.F. Robitaille, L. Jette, C. Benquet, D.J. Drucker, Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo, Diabetes 52 (3) (2003) 751-759.
86. N. Giannoukakis, CJC-1131, ConjuChem. Curr. Opin. Investig. Drugs 4 (10) (2003) 1245-1249.
87. K. Coppieters, T. Dreier, K. Silence, H. de Haard, M. Lauwereys, P. Casteels, E. Beirnaert, H. Jonckheere, C. Van de Wiele, L. Staelens, J. Hostens, H. Revets, E. Remaut, D. Elewaut, P. Rottiers, Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis, Arthritis Rheum. 54 (6) (2006) 1856-1866.
88. A. Wunder, U. Muller-Ladner, E.H. Stelzer, J. Funk, E. Neumann, G. Stehle, T. Pap, H. Sinn, S. Gay, C. Fiehn, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis, J. Immunology 170 (9) (2003) 4793-4801.
89. R. Flisiak, I. Flisiak, Albinterferon-alpha 2b: a new treatment option for hepatitis C, Expert Opin. Biol. Ther. 10 (10) (2010) 1509-1515.
90. D.R. Nelson, Y. Benhamou, W.L. Chuang, E.J. Lawitz, M. Rodriguez-Torres, R. Flisiak, J.W. Rasenack, W. Kryczka, C.M. Lee, V.G. Bain, S. Pianko, K. Patel, P.W. Cronin, E. Pulkstenis, G.M. Subramanian, J.G. McHutchison, Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3, Gastroenterology 139 (4) (2010) 1267-1276.
91. S. Zeuzem, M.S. Sulkowski, E.J. Lawitz, V.K. Rustgi, M. Rodriguez-Torres, B.R. Bacon, M. Grigorescu, A.D. Tice, Y. Lurie, J. Cianciara, A.J. Muir, P.W. Cronin, E. Pulkstenis, G.M. Subramanian, J.G. McHutchison, Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1, Gastroenterology 139 (4) (2010) 1257-1266.
92. C. Chaudhury, C.L. Brooks, D.C. Carter, J.M. Robinson, C.L. Anderson, Albumin binding to FcRn: distinct from the FcRn-IgG interaction, Biochemistry 45 (15) (2006) 4983-4990.
93. C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, C.L. Anderson, The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan, J. Exp. Med. 197 (3) (2003) 315-322.
94. W.P. Faulk, C.G. Taylor, C.J. Yeh, J.A. McIntyre, Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients, Mol. Biother. 2 (1) (1990) 57-60.